volume 2, issue 8, PS398 2007
DOI: 10.1097/01.jto.0000283267.73047.c2
View full text
|
|
Share

Abstract: Background: Non-small-cell lung cancer (NSCLC) patients with locally advanced or metastatic disease at the time of diagnosis show marginal response to chemotherapy in terms of tumor shrinkage, time to progression and median survival. MAP4 and stathmin have been previously reported as potential markers of resistance to treatment based on microtubule-destabilizing agents. Methods: In this multicenter study, we have used quantitative PCR to analyze the expression of MAP4, stathmin, beta-tubulin III, BRCA1 and ERC…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
2
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals